Elektroimportøren AS (OSL:ELIMP)
Norway · Delayed Price · Currency is NOK 16.00
-0.05 (-0.31%)
Aug 1, 2025, 4:25 PM CET
CTI BioPharma Income Statement
Financials in millions NOK. Fiscal year is January - December.
Millions NOK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
Operating Revenue | 1,673 | 1,627 | 1,603 | 1,624 | 1,485 | 1,313 | Upgrade |
Other Revenue | - | - | 1.38 | 2.05 | 0.35 | 3.28 | Upgrade |
| 1,673 | 1,627 | 1,604 | 1,626 | 1,485 | 1,316 | Upgrade | |
Revenue Growth (YoY) | 6.46% | 1.41% | -1.31% | 9.45% | 12.88% | 36.48% | Upgrade |
Cost of Revenue | 1,097 | 1,073 | 1,051 | 1,019 | 912.31 | 798.39 | Upgrade |
Gross Profit | 575.43 | 553.43 | 553.06 | 606.49 | 573.03 | 517.51 | Upgrade |
Selling, General & Admin | 307.92 | 299.92 | 316.14 | 295.62 | 278.09 | 251.8 | Upgrade |
Other Operating Expenses | 105.46 | 103.46 | 101.53 | 104.99 | 72.67 | 61.57 | Upgrade |
Operating Expenses | 525.4 | 514.4 | 512.96 | 492.92 | 428.1 | 384.11 | Upgrade |
Operating Income | 50.04 | 39.04 | 40.1 | 113.57 | 144.92 | 133.4 | Upgrade |
Interest Expense | -46.22 | -44.22 | -46.16 | -36.21 | -20.78 | -24.08 | Upgrade |
Interest & Investment Income | 2.17 | 2.17 | - | - | - | - | Upgrade |
Other Non Operating Income (Expenses) | 39.48 | 46.48 | -9.87 | -10.22 | 0.42 | -5.12 | Upgrade |
EBT Excluding Unusual Items | 45.46 | 43.46 | -15.93 | 67.15 | 124.57 | 104.2 | Upgrade |
Impairment of Goodwill | - | - | - | - | - | -0.01 | Upgrade |
Asset Writedown | - | - | - | - | - | -1.36 | Upgrade |
Pretax Income | 45.46 | 43.46 | -15.93 | 67.15 | 124.57 | 102.83 | Upgrade |
Income Tax Expense | 0.89 | 1.89 | -4.06 | 15.08 | 27.33 | 22.92 | Upgrade |
Earnings From Continuing Operations | 44.57 | 41.57 | -11.87 | 52.07 | 97.24 | 79.91 | Upgrade |
Net Income to Company | - | 41.57 | -11.87 | 52.07 | 97.24 | 79.91 | Upgrade |
Minority Interest in Earnings | 0.03 | 0.03 | 0.08 | - | - | - | Upgrade |
Net Income | 44.6 | 41.6 | -11.79 | 52.07 | 97.24 | 79.91 | Upgrade |
Net Income to Common | 44.6 | 41.6 | -11.79 | 52.07 | 97.24 | 79.91 | Upgrade |
Net Income Growth | - | - | - | -46.46% | 21.69% | 235.17% | Upgrade |
Shares Outstanding (Basic) | 47 | 46 | 24 | 22 | 21 | 21 | Upgrade |
Shares Outstanding (Diluted) | 47 | 46 | 24 | 22 | 21 | 21 | Upgrade |
Shares Change (YoY) | 54.57% | 90.70% | 12.05% | 4.10% | - | - | Upgrade |
EPS (Basic) | 0.95 | 0.90 | -0.49 | 2.41 | 4.69 | 3.85 | Upgrade |
EPS (Diluted) | 0.95 | 0.90 | -0.49 | 2.41 | 4.69 | 3.85 | Upgrade |
EPS Growth | - | - | - | -48.57% | 21.69% | - | Upgrade |
Free Cash Flow | 90.03 | 124.03 | -7.7 | 78.46 | 116.64 | 216.15 | Upgrade |
Free Cash Flow Per Share | 1.91 | 2.69 | -0.32 | 3.63 | 5.63 | 10.43 | Upgrade |
Dividend Per Share | - | - | - | 0.500 | 2.780 | 2.410 | Upgrade |
Dividend Growth | - | - | - | -82.01% | 15.35% | - | Upgrade |
Gross Margin | 34.40% | 34.02% | 34.48% | 37.31% | 38.58% | 39.33% | Upgrade |
Operating Margin | 2.99% | 2.40% | 2.50% | 6.99% | 9.76% | 10.14% | Upgrade |
Profit Margin | 2.67% | 2.56% | -0.73% | 3.20% | 6.55% | 6.07% | Upgrade |
Free Cash Flow Margin | 5.38% | 7.62% | -0.48% | 4.83% | 7.85% | 16.43% | Upgrade |
EBITDA | 71.62 | 61.53 | 71.48 | 139.25 | 167.81 | 154.3 | Upgrade |
EBITDA Margin | 4.28% | 3.78% | 4.46% | 8.57% | 11.30% | 11.73% | Upgrade |
D&A For EBITDA | 21.59 | 22.49 | 31.38 | 25.68 | 22.89 | 20.9 | Upgrade |
EBIT | 50.04 | 39.04 | 40.1 | 113.57 | 144.92 | 133.4 | Upgrade |
EBIT Margin | 2.99% | 2.40% | 2.50% | 6.99% | 9.76% | 10.14% | Upgrade |
Effective Tax Rate | 1.96% | 4.35% | - | 22.46% | 21.94% | 22.29% | Upgrade |
Revenue as Reported | 1,627 | 1,627 | 1,604 | 1,626 | 1,485 | 1,316 | Upgrade |
Updated Feb 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.